comparemela.com

Page 5 - நிதி ப்ரெஸ் வெளியீடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

TodayIR: HSBC doubles EC Healthcare target price to HKD15 00 and reiterates Buy rating EC Healthcare s third advanced imaging service centre commences operation

DJ EQS-News: HSBC doubles EC Healthcare target price to HKD15.00 and reiterates 'Buy' rating EC Healthcare's third advanced imaging service centre commences operation EQS-News / 06/05/2021 / 12:26

TodayIR: CN Logistics (2130 HK) Partners with Redress to Promote Energy Conservation and Waste Reduction in Hong Kong and Macau

(2) DJ EQS-News: CN Logistics (2130.HK) Partners with Redress to Promote Energy Conservation and Waste Reduction in Hong Kong and Macau EQS-News / 03/05/2021 / 11:45 UTC+8 CN Logistics International Holdings Limited (Incorporated in the Cayman Islands with limited liability) (Stock Code: 2130) Green Logistics Wins Support from High-End Fashion Brands CN Logistics Partners with Redress to Promote Energy Conservation and Waste Reduction in Hong Kong and Macau [Hong Kong - 3 May 2021] A well-established international logistics solutions provider, CN Logistics International Holdings Limited (the Company , together with its subsidiaries, the Group , stock code: 2130), is pleased to announce that the Group has been entrusted by many international high-end fashion brand customers to provide its green logistics solutions, which covers consultation on green logistics and carbon footprint reduction, as well as recycling clothes, reusable and recyclable materials and etc. The Group

TodayIR: Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

(1) DJ EQS-News: Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment EQS-News / 29/04/2021 / 11:36 UTC+8 Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment With the official release and implementation of the Overall Plan for the Construction of Hainan Free Trade Port, patient can now access global innovative medicines in mainland China. Recently, the global first-in-class selective inhibitor of nuclear export (SINE) compound, selinexor (XPOVIO(R)), was prescribed for the first time in mainland China at the Boao Super Hospital in Boao Lecheng Pilot Zone and has been authorized to be expanded beyond the Pilot Zone for the outpatient treatment of relapsed or refractory multiple myeloma (rrMM). Prescribing selinex

TodayIR: ADTIGER (1163 HK) Revenue Surged approximately 70% yoy to RMB 82 0 Million to RMB 86 0 Million, Further Promotes Domestic Digital Marketing Business

TodayIR: [9911 HK] Newborn Town Inc Announced 1Q 2021 Operating Figures; Total Revenue for the First Quarter exceeded RMB 500 Million; MAU of Social Networking Apps increased by 25 75% QoQ to over 16 5 mil

(2) DJ EQS-News: [9911.HK] Newborn Town Inc. Announced 1Q 2021 Operating Figures; Total Revenue for the First Quarter exceeded RMB 500 Million; MAU of Social Networking Apps increased by 25.75% QoQ to over 16.5 mil EQS-News / 23/04/2021 / 09:00 UTC+8 Newborn Town Inc. Announced 1Q 2021 Operating Figures Total Revenue for the First Quarter exceeded RMB 500 Million MAU of Social Networking Apps increased by 25.75% QoQ to over 16.5 million 23rd April 2021, Hong Kong - Newborn Town Inc. (stock code: 9911.HK), the leading Chinese internet company with strategic focus on global social networking business announced the unaudited operating figures for the first quarter of 2021. During the Period, the Monthly Active Users (MAU) of social networking applications and mobile games increased significantly, which further boosted the growth in value-added service revenue (in-app purchase revenue). Value-added service revenue is estimated to range from RMB 367 million to RMB 387 million, repr

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.